Authors: Olivia Kelada Laure Marignol
Publish Date: 2014/02/20
Volume: 35, Issue: 6, Pages: 5095-5100
Abstract
Erythropoietinstimulating agents ESAs are used in breast cancer patients with chemotherapyinduced anemia to alleviate anemia and in turn reduce fatigue These drugs may also decrease overall survival and increase the incidence of serious adverse effects such as thrombovascular events TVEs This review evaluates the evidence to date on administering ESAs to breast cancer patients with chemotherapyinduced anemia Our findings suggest a clear need for welldesigned clinical trials that follow current Food and Drug Administration FDA ESA label changes to guide clinical practice in an effort to reduce harm to these patients
Keywords: